Mylan Labs Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Mylan Labs

MYL 15.86

0.0%

Nov 19 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Neil H who wrote (376)	3/24/2004 8:12:35 AM
From: Neil H	Read Replies (1) of 384

Mylan Receives FDA Approval and 180 Day Exclusivity for Nitrofurantoin Wednesday March 24, 6:30 am ET PITTSBURGH--(BUSINESS WIRE)--March 24, 2004--Mylan Laboratories Inc. (NYSE: MYL - News) is pleased to announce that the U.S. Food and Drug Administration has granted final approval for Mylan Pharmaceuticals' Abbreviated New Drug Application for nitrofurantoin monohydrate/macrocrystals capsules, 100 mg. Nitrofurantoin is the generic version of Procter & Gamble's Macrobid®. Mylan was the first company to file a paragraph IV certification for nitrofurantoin, and as such is entitled to 180 days of marketing exclusivity. Mylan intends to ship the product immediately.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next